Allan D. Struthers

Allan D. Struthers

Auto-generated profile, based on publicly available information

Allan D. Struthers

University of Dundee

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 1997 in The Lancet
Verified
Journal Article
Closed access
MCMartin R Cowie
Martin R Cowie
ASAllan D Struthers
Allan D Struthers
DWDavid A Wood
David A Wood
ACAndrew Js Coats
Andrew Js Coats
STSimon G Thompson
Simon G Thompson
GSGeorge C Sutton
George C Sutton

1 February 1994 in The Lancet
Verified
Journal Article
Closed access
CBC.S. Barr
C.S. Barr
ANA. Naas
A. Naas
MFM. Freeman
M. Freeman
CLChim C. Lang
Chim C. Lang
ASA.D. Struthers
A.D. Struthers

5 December 2006 in Circulation
Verified
Journal Article
Closed access
JGJacob George
Jacob George
ECElaine Carr
Elaine Carr
JDJustine Davies
Justine Davies
Jill J.F BelchJill J.F Belch
Jill J.F Belch
ASAllan Struthers
Allan Struthers
Background— Allopurinol has been shown to improve endothelial function in chronic heart failure. This study aimed to establish its mechanism of action and to construct a dose–response curve for the effect of allopurinol. Methods and Results— Two randomized, placebo-controlled, double-blind, crossover studies were performed for 1 month on patients with New York Heart Association Class II–III chronic heart failure, comparing 300 mg allopurinol, 600 mg allopurinol, and placebo for the first study and 1000 mg probenecid versus placebo in the second study. Endothelial function was assessed by standard forearm venous occlusion plethysmography. Allopurinol 600 mg/d significantly increased forearm blood flow response to acetylcholine compared with both allopurinol 300 mg/d and placebo (% change in forearm blood flow [mean±SEM]: 240.31±38.19% versus 152.10±18.21% versus 73.96±10.29%, P <0.001). For similar levels of urate lowering, the uricosuric agent probenecid had no effect on endothelial function. Sodium nitroprusside response was unchanged by all treatments. Vitamin C and acetylcholine coinfusion data showed that 600 mg/d allopurinol completely abolished the oxidative stress that was sensitive to high-dose vitamin C. Conclusions— For the first time, we have shown that a steep dose–response relationship exists between allopurinol and its effect on endothelial function. We also showed that the mechanism of improvement in endothelial function with allopurinol lies in its ability to reduce vascular oxidative stress and not in urate reduction. The reduction in vascular oxidative stress was profound because high-dose allopurinol totally abolished the oxidative stress that was sensitive to the high-dose vitamin C that was used in this study.

27 February 2008 in Diabetic Medicine
Verified
Journal Article
Closed access
PDF file
JSJ. A. Sugden
J. A. Sugden
JDJ. I. Davies
J. I. Davies
MWMiles D. Witham
Miles D. Witham
AMA. D. Morris
A. D. Morris
ASA. D. Struthers
A. D. Struthers

15 February 2000 in Circulation
Verified
Journal Article
Closed access
PDF file
CFColin A. J. Farquharson
Colin A. J. Farquharson
ASAllan D. Struthers
Allan D. Struthers
Background —The RALES study showed that spironolactone, added to conventional therapy for chronic heart failure, dramatically reduced mortality. We tested the hypothesis that this benefit was partially due to improvement in endothelial function and/or to amplified suppression of the vascular renin-angiotensin axis. Methods and Results —We performed a randomized, placebo-controlled, double-blind crossover study on 10 patients with NYHA class II to III chronic heart failure on standard diuretic/ACE inhibitor therapy, comparing 50 mg/d spironolactone (1 month) versus placebo. Forearm vasculature endothelial function was assessed by bilateral forearm venous occlusion plethysmography using acetylcholine and N -monomethyl- l -arginine (L-NMMA), with sodium nitroprusside as a control vasodilator. Also, vascular ACE activity was assessed by use of angiotensin (Ang) I, with Ang II as a control vasoconstrictor. Spironolactone significantly increased the forearm blood flow response to acetylcholine (percentage change in forearm blood flow [mean±SEM], 177±29% versus 95±20%, spironolactone versus placebo; P <0.001), with an associated increase in vasoconstriction due to L-NMMA (−35±6% versus −18±4%; P <0.05). The Ang I response was also significantly reduced with spironolactone ( P <0.05), with Ang II responses unaltered. Conclusions —Spironolactone improves endothelial dysfunction, increases NO bioactivity, and inhibits vascular Ang I/Ang II conversion in patients with heart failure, providing novel mechanisms for its beneficial effect on cardiovascular mortality.

9 July 2002 in Circulation
Verified
Journal Article
Closed access
PDF file
CFColin A.J. Farquharson
Colin A.J. Farquharson
RBRobert Butler
Robert Butler
AHAlexander Hill
Alexander Hill
Jill J.F BelchJill J.F Belch
Jill J.F Belch
ASAllan D. Struthers
Allan D. Struthers
Background — Increased oxidative stress in chronic heart failure is thought to contribute to endothelial dysfunction. Xanthine oxidase produces oxidative stress and therefore we examined whether allopurinol improved endothelial dysfunction in chronic heart failure. Methods and Results — We performed a randomized, placebo-controlled, double-blind crossover study on 11 patients with New York Heart Association class II-III chronic heart failure, comparing 300 mg allopurinol daily (1 month) versus placebo. Endothelial function was assessed by standard forearm venous occlusion plethysmography with acetylcholine, nitroprusside, and verapamil. Plasma malondialdehyde levels were also compared to assess significant changes in oxidative stress. Allopurinol significantly increased the forearm blood flow response to acetylcholine (percentage change in forearm blood flow [mean±SEM]: 181±19% versus 120±22% allopurinol versus placebo; P =0.003). There were no significant differences in the forearm blood flow changes between the placebo and allopurinol treatment arms with regard to sodium nitroprusside or verapamil. Plasma malondialdehyde was significantly reduced with allopurinol treatment (346±128 nmol/L versus 461±101 nmol/L, allopurinol versus placebo; P =0.03), consistent with reduced oxidative stress with allopurinol therapy. Conclusions — We have shown that allopurinol improves endothelial dysfunction in chronic heart failure. This raises the distinct possibility that allopurinol might reduce cardiovascular events and even improve exercise capacity in chronic heart failure.